Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INTERCEPT: INTracerebral EGFR-vIII Chimeric Antigen Receptor Gene-Modified T CElls for PaTients With Recurrent GBM

NCT03283631 is registered in ClinicalTrials.gov with Gary Archer Ph.D. as lead sponsor.

NCT NCT03283631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03283631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INTERCEPT: INTracerebral EGFR-vIII Chimeric Antigen Receptor Gene-Modified T CElls for PaTients With Recurrent GBM
Lead sponsor
Gary Archer Ph.D.
Phase
Phase 1
Overall status
Terminated
Start date
May 30, 2018
Completion date
June 30, 2020
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma, recurrent gliosarcoma